CN115300531A - Lactobacillus paracasei JY062 composition and preparation method and application thereof - Google Patents
Lactobacillus paracasei JY062 composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN115300531A CN115300531A CN202211072208.5A CN202211072208A CN115300531A CN 115300531 A CN115300531 A CN 115300531A CN 202211072208 A CN202211072208 A CN 202211072208A CN 115300531 A CN115300531 A CN 115300531A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- supernatant
- centrifuging
- intestinal
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000006378 damage Effects 0.000 claims abstract description 21
- 230000000968 intestinal effect Effects 0.000 claims abstract description 17
- 229920002444 Exopolysaccharide Polymers 0.000 claims abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 13
- 208000014674 injury Diseases 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000006228 supernatant Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000001963 growth medium Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 14
- 238000009630 liquid culture Methods 0.000 claims description 14
- 150000004676 glycans Chemical class 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 229940099596 manganese sulfate Drugs 0.000 claims description 4
- 235000007079 manganese sulphate Nutrition 0.000 claims description 4
- 239000011702 manganese sulphate Substances 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 210000005027 intestinal barrier Anatomy 0.000 claims description 3
- 230000004673 intestinal mucosal barrier function Effects 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims 1
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 23
- 102000003945 NF-kappa B Human genes 0.000 abstract description 21
- 108010057466 NF-kappa B Proteins 0.000 abstract description 21
- 230000004888 barrier function Effects 0.000 abstract description 20
- 230000006870 function Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 7
- 230000008944 intestinal immunity Effects 0.000 abstract description 3
- 210000001072 colon Anatomy 0.000 description 51
- 210000001519 tissue Anatomy 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 36
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 28
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 18
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 210000000068 Th17 cell Anatomy 0.000 description 16
- 210000003289 regulatory T cell Anatomy 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 14
- 102100035100 Transcription factor p65 Human genes 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 102000003940 Occludin Human genes 0.000 description 11
- 108090000304 Occludin Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 102000013691 Interleukin-17 Human genes 0.000 description 10
- 108010063954 Mucins Proteins 0.000 description 10
- 102000015728 Mucins Human genes 0.000 description 10
- 108090000580 Claudin-2 Proteins 0.000 description 9
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 9
- -1 carbohydrate compound Chemical class 0.000 description 9
- 102000004162 Claudin-1 Human genes 0.000 description 8
- 108090000600 Claudin-1 Proteins 0.000 description 8
- 102000004056 Claudin-2 Human genes 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 7
- 102100034263 Mucin-2 Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000002175 goblet cell Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- 102000000591 Tight Junction Proteins Human genes 0.000 description 6
- 108010002321 Tight Junction Proteins Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108010008705 Mucin-2 Proteins 0.000 description 5
- 108010031154 Transcription Factor RelA Proteins 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 102000005747 Transcription Factor RelA Human genes 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000002029 Claudin Human genes 0.000 description 3
- 108050009302 Claudin Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000008379 I-kappa B Proteins Human genes 0.000 description 3
- 108010021699 I-kappa B Proteins Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003870 intestinal permeability Effects 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 235000019722 synbiotics Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003690 classically activated macrophage Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000004106 Claudin-3 Human genes 0.000 description 1
- 108090000599 Claudin-3 Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101710186071 Interleukin-17 receptor B Proteins 0.000 description 1
- 102100035014 Interleukin-17 receptor B Human genes 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 101100524295 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) relB3 gene Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000727058 Mus musculus Complement component receptor 1-like protein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101800004006 Protein p50 Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 101150023313 relB gene Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000005491 wire drawing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a lactobacillus paracasei JY062 composition, which comprises lactobacillus paracasei JY062 (B)Lactobacillus paracasei JY 062) and lactobacillus paracasei JY 062; the content of the lactobacillus paracasei JY062 is not less than 10 9 CFU/mL; the concentration of the exopolysaccharide is not lower than 30mg/mL. The invention also discloses a preparation method of the lactobacillus paracasei JY062 composition. The invention also discloses a Lactobacillus paracasei JY062 compositionApplication in preparing health products and functional foods for enhancing intestinal immunity activity; and application thereof in preparing medicines, health products and functional foods for improving intestinal mucosa barrier injury. The invention has the functions of obviously enhancing the intestinal immunocompetence and improving the intestinal mucosa barrier damage through the NF-kB signal path.
Description
Technical Field
The invention relates to a lactobacillus paracasei JY062 composition, a preparation method and an application thereof, and belongs to the technical field of microorganisms.
Background
The lactobacillus is generally regarded as safe food-grade bacteria, most of the lactobacillus is regarded as probiotics, lactobacillus paracasei is a probiotic which is researched more recently, belongs to lactobacillus, widely exists in traditional fermented dairy products and human gastrointestinal tracts, can effectively adhere to and colonize intestinal mucosa, regulates and controls intestinal flora, epithelial cells and immune factors in intestinal microenvironment steady state, performs immune regulation, and maintains intestinal steady state; the extracellular polysaccharide which is an important metabolite of the lactobacillus is a carbohydrate compound secreted by the lactobacillus in a tightly combined capsule or loosely attached mucus layer form, secreted outside a cell wall in a growth and metabolism process and often permeated in a culture medium, plays an important regulation role on an organism intestinal tract mainly by improving the adhesion of the intestinal mucosa, regulating the intestinal microecological balance and supplying energy to the intestinal tract in the interaction process of the extracellular polysaccharide and host intestinal tract cells, and realizes the probiotic function of the lactobacillus by the EPS function on one hand and the metabolism of the probiotics on the other hand.
The synbiotics are composed of probiotics and prebiotics, and play an important role in improving immune response, relieving intestinal inflammation, reducing oxidative stress, maintaining intestinal epithelial cell barrier function, adjusting short-chain fatty acid level, improving intestinal flora structure and the like by promoting the probiotics to colonize and proliferate in the intestinal tract of a host and simultaneously playing a role in promoting the physiological activity of the probiotics and the growth promotion of the prebiotics.
The NF-. Kappa.B/Rel protein family includes five members: c-Rel, relA (p 65), relB, NF-. Kappa.B 1 (p 50/p 105) and NF-. Kappa.B 2 (p 52/p 100), which exist as homo-or heterodimers, the NF-. Kappa.B 1 dimeric protein p65/p50 (most commonly) and the NF-. Kappa.B dimeric protein RelB/p52. When the organism is in a resting state, NF-kB is combined with an inhibitory protein I-kB (inhibit NF-kB) in cytoplasm to present an inactive state; when the organism is stimulated by the outside, the I-kB kinase (inhibitor of NF-kB kinase, IKK) can phosphorylate the NF-kB inhibitor I-kB, so that the I-kB is degraded, the NF-kB is released from an I-kB complex and separated from the I-kB, and free NF-kB enters the cell nucleus from cytoplasm and is combined with a specific binding site to regulate the transcription of a target gene, so that an NF-kB signal channel is activated. The NF-kB system can maintain the homeostasis of normal intestinal epithelium and plays a central role in mucosal immune response; but also can mediate pathogen specific response, and is a double-edged sword for the mucous membrane barrier.
The increase of intestinal permeability causes harmful bacteria to enter the inner layer of a mucous membrane, the secretion amount of mucin is greatly reduced, and intestinal epithelial cells are largely apoptotic to cause local environmental disorder of the intestinal tract. Tight junctions, the most prominent way to connect between intestinal epithelial cells, are located at the boundaries of the top and outer membranes of the intestinal epithelial cells, and are a highly diverse structure composed of transmembrane and cytoplasmic proteins. Occluding proteins Occludin, occludin and Occludin (ZO-1, ZO-2 and ZO-3) are important protein molecules which constitute the barrier integrity of intestinal mucosa and determine the permeability of intestinal tracts, and serve as the most important 3 tight junction proteins. Intestinal endocrine mucus is mainly composed of Mucin (Mucin) secreted from goblet cells and forms a mucus layer inside the intestinal lumen, wherein Mucin2 is a main substance constituting the mucus layer. A great deal of research shows that the traditional Chinese medicine composition can stimulate goblet cells to secrete mucin and increase the thickness of a mouse mucus layer to improve barrier function by preventing the increase of intestinal permeability; up-regulating the expression of intestinal epithelial cell mucin MUC2, claudin-3, ZO-1 and E-cadherin to restore the integrity of the intestinal mucosal barrier.
Therefore, the lactobacillus paracasei JY062 composition, the preparation method and the application thereof have practical significance for realizing the function of accurately intervening lactobacillus and metabolic active substances thereof in regulating and controlling the health of host intestinal tracts, and provide theoretical basis for developing probiotics and potential prebiotics functional preparations.
Disclosure of Invention
The invention aims to provide a lactobacillus paracasei JY062 composition, which consists of lactic acid bacteria (namely lactobacillus paracasei JY 062) and extracellular polysaccharide.
Meanwhile, the invention provides a preparation method of the lactobacillus paracasei JY062 composition, and the composition obtained by the method has the functions of obviously enhancing the intestinal immunity activity and improving the intestinal mucosa barrier injury through the NF-kB signal path.
Meanwhile, the invention provides application of the lactobacillus paracasei JY062 composition in preparation of medicines, health-care products and functional foods for enhancing intestinal immunocompetence.
Meanwhile, the invention provides application of the lactobacillus paracasei JY062 composition in preparation of medicines, health-care products and functional foods for improving intestinal mucosa barrier injury.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a Lactobacillus paracasei j062 composition, comprising exopolysaccharides of Lactobacillus paracasei j062 (Lactobacillus paracasei j062) and Lactobacillus paracasei j062; the content of lactobacillus paracasei JY062 is not less than 10 9 CFU/mL; the concentration of the exopolysaccharide is not lower than 30mg/mL.
A method of preparing a lactobacillus paracasei JY062 composition, the method comprising the steps of:
step one, inoculating lactobacillus paracasei JY062 into a sterilized MRS liquid culture medium according to the inoculation amount of 5 percent, wherein the initial concentration is 1.5 multiplied by 10 9 CFU/mL；
Step two, adding the compound carbon source in an equal amount by using the optimized compound carbon source MRS liquid culture medium; culturing at 34 deg.C in a fermenter at 100rpm/min for 25h, and supplementing 20% w/v of ammonia water during fermentation; after fermenting for 12 hours, starting to supplement 100mL/30min of MRS liquid culture medium until the end, and collecting bacterial liquid;
centrifuging the bacterial liquid, taking the supernatant I, and repeating the step twice;
step four, taking the supernatant I, and concentrating the volume to 1/3 of the original volume to obtain a culture medium;
step five, inactivating enzyme of the culture medium, cooling to room temperature, and collecting supernatant liquid II;
removing protein from the supernatant fluid II, and centrifuging to obtain a supernatant fluid III;
step seven, precipitating the supernatant liquid III with ethanol, centrifuging and taking the precipitate;
step eight, resuspending the pellet in deionized water to obtain polysaccharide solution, placing the polysaccharide solution in an MD34 dialysis bag, wherein the molecular weight cut-off is as follows: 8KD-14KD, dialyzing in deionized water at 4 deg.C for 48h, and replacing deionized water every 8 h;
and step nine, pouring the dialyzed polysaccharide supernatant into a flat plate, placing the flat plate in a refrigerator at the temperature of minus 80 ℃ for pre-freezing overnight, then carrying out freeze drying for 24 hours, and carrying out freeze drying to obtain the exopolysaccharide.
In the first step, the MRS liquid culture medium comprises the following components: 10g/L peptone, 8g/L beef powder, 4g/L yeast powder, 20g/L glucose, 2g/L diammonium hydrogen citrate, 2g/L dipotassium hydrogen phosphate, 5g/L sodium acetate, 0.2g/L magnesium sulfate, 0.04g/L manganese sulfate and 1g/L Tween-80; dissolving 52.24g of the components in 1000mL of distilled water, stirring by a glass rod, carrying out autoclaving at 121 ℃ for 15min, and obtaining the MRS liquid culture medium.
In the second step, the optimized composite carbon source MRS liquid culture medium comprises the following components: 10g/L peptone, 8g/L beef powder, 4g/L yeast powder, 2g/L diammonium hydrogen citrate, 2g/L dipotassium hydrogen phosphate, 5g/L sodium acetate, 0.2g/L magnesium sulfate, 0.04g/L manganese sulfate, 1g/L Tween-80, 3.33g/L fructose, 3.33g/L mannose, 3.33g/L trehalose, 3.33g/L glucose, 3.33g/L galactose and 3.33g/L lactose; dissolving 52.24g of the components in 1000mL of distilled water, stirring with a glass rod, carrying out high-pressure sterilization at 121 ℃ for 15min, and obtaining the optimized composite carbon source MRS liquid culture medium.
The centrifugal process comprises the following steps: centrifuging at 10000r/min and 4 deg.C for 15min.
In the fifth step, the process for inactivating enzyme comprises the following steps: heating in boiling water for 10min.
In the sixth step, the process for removing protein comprises the following steps: adding 80% w/v of trichloroacetic acid to the supernatant II to a final concentration of 10% w/v, stirring for 5min, standing at 4 deg.C for 10h,10000r/min, and centrifuging at 4 deg.C for 15min to remove protein.
In the seventh step, the alcohol precipitation process comprises: adding 2-3 times volume of anhydrous ethanol into the supernatant III to make the final concentration 70%, standing overnight at 4 deg.C, centrifuging at 10000r/min at 4 deg.C for 15min.
Application of Lactobacillus paracasei JY062 composition in preparation of health products and functional foods for enhancing intestinal immunocompetence.
Application of Lactobacillus paracasei JY062 composition in preparation of medicines, health-care products and functional foods for improving intestinal mucosa barrier injury.
The invention has the following beneficial effects:
the invention provides a composition with intestinal immunoregulation function according to the result of synbiotics immunoregulation related research, and the subtype and distribution condition of colon macrophages are evaluated by an immunofluorescence staining method; detecting the content of Th17 and Treg cells in spleen and peripheral blood of the mouse by flow cytometry; ELISA detected 7 immune-related genes and 3 immunoglobulins. The invention overcomes the defects of the conventional lactobacillus paracasei and the evaluation of the immunoregulation function of extracellular polysaccharide generated by the lactobacillus paracasei, and can objectively evaluate the intestinal tract immune barrier regulation effect of the lactobacillus paracasei JY062 and the extracellular polysaccharide generated by the lactobacillus paracasei on a host; discloses a deep mechanism for synergistically regulating intestinal immunity by virtue of lactobacillus paracasei JY062 and exopolysaccharide produced by the lactobacillus paracasei.
Meanwhile, the invention provides a composition for improving the barrier damage function of the intestinal mucosa through an NF-kB signal path, the damage condition of mouse colon tissues is reflected through HE staining, the activity of the NF-kB signal path of the colon is determined by combining RT-PCR with a Western Blot method, and the expression quantity of colon tight junction protein and mucin is determined by combining RT-PCR with an immunohistochemical method. The invention deeply excavates the function of preventing the damage of the intestinal mucosa, analyzes the potential mechanism of the intestinal mucosa immunity, provides a theoretical basis for developing synbiotics with the function of improving the barrier damage of the intestinal mucosa, and can make up the defects of the existing application level to a certain extent.
Drawings
FIG. 1 shows the content of genes related to colon immunity in mice; wherein, a: TNF-alpha; b: IFN-gamma; c: IL-1 β; d: IL-6; e: TGF-beta;
FIG. 2 shows the serum immunoglobulin content of mice; wherein, a: igA; b: igG; c: an IgM;
FIG. 3 is a graph showing the change in the number of Treg cells in the spleen and peripheral blood of mice;
FIG. 4 is a graph showing the change in the number of Th17 cells in the spleen and peripheral blood of mice;
FIG. 5 shows the IL-17 content of the specific cytokine associated with colon Th17 cells in mice;
FIG. 6 shows the IL-10 content of the specific cell factor related to the mouse colon Treg cells;
FIG. 7 shows the subtype and distribution of mouse colon macrophages; wherein, a: type M1;
FIG. 8 shows the subtype and distribution of mouse colon macrophages; wherein, b: m2 type;
FIG. 9 is a histopathological observation of the colon of mice; wherein, a: HE dyeing; b: histological lesion scoring;
FIG. 10 shows the relative expression amounts of genes related to TLR4/MyD88/NF- κ B signaling pathway mRNA; wherein, a: NF-. Kappa.B p65; b: myD88; c: i kappa B; d: TLR4;
FIG. 11 shows the expression level of key proteins in TLR4/MyD88/NF- κ B signaling pathway; wherein, a: NF- κ B p65; b: p-NF-kB p65; c: myD88; d: i kappa B; e: p-I kappa B; f: TLR4;
FIG. 12 shows the relative expression levels of claudin and mucin mRNA in colon tissues of mice; wherein, a: claudin-1; b: claudin-2; c: occludin; d: ZO-1; e: MUC2;
FIG. 13 is a graph of immunohistochemical staining of claudin and mucin in colon tissue in mice;
FIG. 14 is the mean optical density values for claudin and mucin in murine colon tissue; wherein, a: claudin-1; b: claudin-2; c: occludin; d: ZO-1; e: MUC2.
Detailed Description
The present invention will be further described with reference to the accompanying drawings.
In the invention, the Latin name of the Lactobacillus paracasei JY062 is Lactobacillus paracasei JY062, the Lactobacillus paracasei JY062 is preserved in a milk product key laboratory of northeast agriculture university and is separated from a Tibet traditional fermented milk product, and the prior art sources of the Lactobacillus paracasei JY062 are as follows: the adhesiveness and the tolerance of a high-yield exopolysaccharide hypoglycemic lactobacillus paracasei JY062 (TD 062) are evaluated [ J ]. China dairy industry, 2022, 50 (4).
Zhangyu, jiangyuyujun, dandangfang, and the like, lactobacillus paracasei TD062 has the hypoglycemic effect on type II diabetic mice [ J ] Chinese food academy 2020, v.20 (05): 112-118.
The public is available from the northeast university of agriculture.
Example 1
A Lactobacillus paracasei JY062 composition comprises exopolysaccharides of Lactobacillus paracasei JY062 (Lactobacillus paracasei JY 062) and Lactobacillus paracasei JY 062; the content of the lactobacillus paracasei JY062 is 10 9 CFU/mL; the concentration of the exopolysaccharide is 30mg/mL.
A method of preparing a lactobacillus paracasei JY062 composition, the method comprising the steps of:
(1) Lactobacillus paracasei JY062 was inoculated into sterilized MRS liquid medium at 5% inoculum size, with an initial concentration of 1.5X 109CFU/mL.
(2) And (3) adding the optimized composite carbon source MRS liquid culture medium in an equivalent manner. Culturing at 34 deg.C in a fermenter at 100rpm/min for 25 hr, supplementing 20% (w/v) ammonia water in time during fermentation, supplementing MRS liquid culture medium after 12 hr fermentation, and collecting bacterial liquid.
(3) Centrifuging the bacterial solution at 10000r/min and 4 deg.C for 15min, collecting supernatant, and repeating the steps twice.
(4) Taking the supernatant, concentrating in a rotary evaporator, and concentrating to 1/3 of the original volume.
(5) Heating the culture medium in boiling water for 10min to inactivate enzyme, cooling to room temperature, and collecting supernatant.
(6) Adding 80% (w/v) trichloroacetic acid into the supernatant to a final concentration of 10% (w/v), stirring for 5min, standing at 4 deg.C for 10h,10000r/min, centrifuging at 4 deg.C for 15min to remove protein, and collecting the supernatant.
(7) Adding 2-3 times volume of anhydrous ethanol into the supernatant to make its final concentration 70%, standing overnight at 4 deg.C, centrifuging at 10000r/min at 4 deg.C for 15min, and collecting precipitate.
(8) The precipitate was resuspended in deionized water, the polysaccharide solution was placed in an MD34 dialysis bag (molecular weight cut-off: 8KD-14 KD), dialyzed in deionized water at 4 ℃ for 48h, and the deionized water was changed every 8 h.
(9) And pouring the dialyzed polysaccharide supernatant into a flat plate, pre-freezing the flat plate in a refrigerator at the temperature of-80 ℃ overnight, and then freeze-drying the flat plate for 24 hours. And (5) freeze-drying to obtain the exopolysaccharide.
The lactobacillus paracasei JY062 composition obtained by the embodiment is applied to preparation of medicines, health-care products and functional foods for enhancing intestinal immunocompetence.
The immunity enhancing activity is to regulate the content of immunity related gene, inhibit excessive secretion of proinflammatory factors (TNF-alpha, IFN-gamma, IL-1 beta and IL-6) and increase the level of anti-inflammatory factors (TGF-beta).
The immunity enhancing effect is obtained by reducing immunoglobulin (IgA, igG, igM) content to normal level.
The immunity enhancing function is to reduce the number of Th17 cells and the content of the related specific cytokine IL-17, and increase the number of Treg cells and the content of the related specific cytokine IL-10.
Enhancing immunity can regulate M1/M2 type macrophage balance, inhibit colon macrophage polarization to M1 type, and promote colon macrophage polarization to M2 type.
The composition is a functional food or health product.
The test animals are male C57BL/6J 8-week-old and 25-30g in weight, and purchased from Liaoning Biotechnology GmbH.
Animal grouping: the experimental animals selected 60 male C57BL/6J with age of 8 weeks and weight of 25-30g, the basal feed was adaptively fed for 1 week and then adapted to the environment, and the experimental animals were randomly divided into 5 groups (n = 12) which were blank Control (NC), model (3 DSS) and single-strain group (10% 9 CFU/mL, JY 062), monosaccharide group (600 mg/kg, EPS), saccharomycete complex group (10) 9 CFU/mL +600mg/kg, JEC), numbered with picric acid. Mice in the blank control group were fed with normal diet and free water throughout the experiment (1-21 d), and the dry control group (JY 062, EPS, JEC) was gavaged regularly every day for the whole experiment period (8-21 d), with a gavage dose of 200 μ L. At the modeling stage (15-21 d) after one week of gavage, the remaining groups were induced by adding 3% DSS aqueous solution, except for the blank control group.
1. ELISA method for determining in vivo immune related genes:
taking out 50-100mg of colon tissue from a-80 ℃ refrigerator (after the test period is finished, the colon tissue is killed and taken out to be placed in the-80 ℃ refrigerator), using precooled sterile PBS as a homogenization medium, and mixing the colon tissue with the mixed solution according to the weight of the colon tissue: the volume of the homogenization medium was 1. Completely transferring 10% of the tissue homogenate into a brand-new centrifuge tube, centrifuging (4 ℃,12000rpm, 10min), collecting supernatant, and repeating the centrifugation twice, wherein the contents of TNF-alpha, IFN-gamma, IL-1 beta, IL-6 and TGF-beta in the colon tissue are detected by adopting a competition method according to an enzyme linked immunosorbent assay kit instruction.
2. Determination of the immunoglobulin content in vivo by ELISA:
blood sampling is carried out by removing the eyeballs of the mice, and the eyeballs are clamped after being engorged with blood to collect the eye blood in a 1.5mL sterile centrifuge tube. Placing the blood around the eyes of the mouse on ice for 2 hours to fully separate out the serum, centrifuging (4 ℃,12000rpm, 10min), taking the upper serum, unfreezing on ice, placing the ELISA kit at room temperature for 30min in advance, carrying out specific operation according to the kit specification, measuring absorbance at the wavelength of 492nm by using a multifunctional enzyme label instrument, drawing a standard curve (taking the concentration of a standard product as a horizontal coordinate and A492nm as a vertical coordinate) according to requirements, and calculating the content of immunoglobulin IgA, igG and IgM in the serum.
3. Measuring the content of specific cytokines related to the Th17 and Treg cells in vivo by an ELISA method:
taking 50-100mg of colon tissue out of a refrigerator at-80 ℃, using precooled sterile PBS as a homogenizing medium, and mixing the components according to the weight of the colon tissue: the volume of the homogenization medium was 1. Transferring 10% of the tissue homogenate completely into a brand-new centrifuge tube, centrifuging (4 ℃,12000rpm, 10min), collecting the supernatant, and repeating the centrifugation twice, wherein the contents of IL-17 and IL-10 in the colon tissue are detected by adopting a competition method by referring to an enzyme linked immunosorbent assay kit instruction.
4. Detecting the content of Th17 and Treg cells in spleen and peripheral blood of the mouse by flow cytometry:
removing the eyeball of the mouse and taking blood, collecting the blood into an anticoagulation tube; adding 1 Xerythrocyte lysate, gently blowing blood, mixing, centrifuging at 4 deg.C (600g, 10 min), and discarding supernatant until erythrocyte lysis is complete; adding PBS, resuspending, centrifuging at 4 deg.C (600g, 10 min), washing for 1 time, adding appropriate amount of 1 XPBS (100 uL per tube); according to the weight ratio of 1.25: adding PE/Cyanine 7anti-mouse CD3, 0.5: adding FITC anti-mouse CD4 and 5 in a volume ratio of 100: adding APC/Cyanine7anti-mouse CD25 surface antibody at the volume ratio of 100, and keeping out of the light for 30min at 4 ℃; after adding PBS for resuspension, the cells were centrifuged at 4 ℃ for 600g and 10min to disrupt nuclei. In this example, g of 600g represents the rotation speed, which can be converted to rpm, involved in the centrifugal operation.
Taking out eyeballs, killing the mice by a cervical dislocation method, dissecting, quickly separating out spleens by using forceps, putting the spleens into a 5mL EP tube, and shearing; adding collagenase IV, and digesting in a constant temperature shaking box (37 ℃,25min, 100rpm); adding FBS to stop digestion when the tissue fluid is turbid and is in a wiredrawing state; filtering, grinding, washing with PBS, centrifuging at 4 deg.C (600g, 10 min), discarding supernatant, adding 1 × erythrocyte lysate, gently blowing, mixing, and lysing for 2min; discarding the supernatant; adding PBS, resuspending, centrifuging at 4 deg.C (600g, 10 min), washing for 1 time, adding appropriate amount of 1 XPBS (100 uL per tube); according to the weight ratio of 1.25: adding PE/Cyanine 7anti-mouse CD3, 0.5: adding FITC anti-mouse CD4 and 5 in a volume ratio of 100: adding APC/Cyanine7anti-mouse CD25 according to the volume ratio of 100, and keeping out of the sun for 30min at 4 ℃; after adding PBS for resuspension, the cells were centrifuged at 4 ℃ for 600g and 10min to disrupt nuclei.
Adding True-N into each tubeuclear TM 1 XFix concentrator, vortex shaking and incubation in the dark at room temperature for 55min; adding True-Nuclear to each tube TM 1 XPerm Buffer, centrifuging at room temperature (400g, 5 min), and discarding the supernatant, and repeating this step twice; adding True-Nuclear TM 1 XPerm Buffer, according to 1.25: adding APC anti-mouse IL-17RB and 5: adding PE anti-mouse FOXP3 according to the volume proportion of 100, and incubating for 30min at room temperature in a dark place; adding True-Nuclear TM 1 XPerm Buffer, centrifuging at room temperature (400g, 5 min), and discarding the supernatant; adding cell staining buffer solution, centrifuging at room temperature (400g, 5 min), and then removing supernatant; adding cell staining buffer solution for resuspension, and performing on-machine detection on the levels of Treg cells and Th17 cells by an Agilent flow cytometer.
5. The subtype and distribution of colon macrophages are evaluated by immunofluorescence staining:
the colon tissue after embedding section is dewaxed by xylene to water, repaired antigen, immunohistochemical drawing out the tissue circle, 3% BSA serum blocking, adding primary antibody for incubation overnight at 4 ℃ (CD 68, CD86, CD 206), adding secondary antibody (HRP enzyme label) covering tissue of primary antibody corresponding species for incubation at room temperature for 20min, adding TSA reagent, DAPI counterstaining cell nucleus, mounting, and finally observing under a fluorescence microscope and photographing and recording.
6. Results and analysis:
as can be seen from FIG. 1, compared with the NC group, the levels of proinflammatory cytokines (TNF-alpha, IFN-gamma, IL-6 and IL-1 beta) in colon tissues of mice in the DSS group are remarkably increased, and the level of TGF-beta is remarkably reduced (P < 0.0001); compared with DSS group, the levels of TNF-alpha, IL-1 beta, IFN-gamma and IL-6 in JEC complex group are reduced to different degrees (P <0.0001, P <0.001, P < 0.05), and the level of TGF-beta of anti-inflammatory cytokine is increased significantly (P < 0.0001). The JEC compound can effectively regulate the level of mouse cell factors, maintain the balance of proinflammatory factors and anti-inflammatory factors in colon tissues, relieve the inflammation of mice and enhance the intestinal resistance of the mice.
As can be seen from FIG. 2, compared with the NC group, the levels of IgG, igM and IgA in the serum of mice in the DSS group are significantly increased (P < 0.0001). Compared with the DSS group, the levels of IgG and IgM in the JEC complex group are reduced to different degrees (P <0.0001 and P < 0.001). The level of the immune globulin reflects the activity degree of B cell reaction, has important regulation and control effects on the excitation and maintenance of B cell immunity, and the JEC compound can relieve the abnormal expression of serum IgG, igM and IgA levels, thereby showing that the JEC compound has an immune regulation function and corrects the immune dysfunction of intestinal mucosa.
As can be seen from fig. 3 (which is a graph of CD4+ CD25+ Foxp3+ Treg cells in spleen and peripheral blood of each group), the levels of CD4+ CD25+ Foxp3+ Treg cells in DSS group in spleen and peripheral blood were the lowest, 14.08% and 1.17%, respectively, and thus it can also be seen that there is a difference in Treg cell content in different immune organs. JEC complexes increased Treg cell levels in spleen and peripheral blood (P <0.001, P-but-0.0001) to varying degrees, 38.23%, 5.87%, respectively, compared to DSS groups. The spleen Treg cell content after the JEC compound is dried is increased by nearly 3 times compared with the DSS group, and the peripheral blood is increased by nearly 5 times. The JEC complex can promote Treg cell differentiation.
As shown in FIG. 4 (the CD3+ CD4+ IL-17+ Th17 cell map in spleen and peripheral blood of each group), the levels of IL-17+ CD4+ Th17 cells in DSS group in spleen and peripheral blood are the highest, respectively 18.83% and 24.34%, and different from Treg cells, the content difference of Th17 cells in different immune organs is not very large. The JEC complex down-regulated Th17 cell levels in spleen and peripheral blood (P < 0.01) 7.40%, 17.27% compared to DSS group, respectively. The spleen Th17 cell content after JEC compound drying is reduced by 2.5 times compared with the DSS group, while the peripheral blood is reduced by nearly 1.5 times, and the Th17 cell content in the peripheral blood is close to that in the NC group (14.58%). The balance between Th17 and Treg is crucial to immune homeostasis, and Th17 and Treg can be transformed with each other in the differentiation process, and the results show that the JEC compound can inhibit the differentiation of Th17 cells, thereby maintaining immune homeostasis.
As can be seen from FIG. 5, the ELISA detected the IL-10 content of the specific cytokine related to the mouse colon Treg cells, compared with the NC group, the level of IL-10 in the colon tissue of the mice in the DSS group was significantly reduced (P < 0.0001), compared with the DSS group, the IL-10 content in the JEC complex group was significantly increased (P < 0.0001), and the content was 242.863pg/mL, even the IL-10 content in the NC group (233.027 pg/mL). The specific anti-inflammatory cytokine IL-10 mainly secreted by Treg cells plays an important role in inhibiting inflammatory reaction and autoimmune diseases.
As can be seen from FIG. 6, the ELISA detected the IL-17 content of the Th17 cell-associated specific cytokine in the colon of mice, compared with the NC group, the level of IL-17 in the colon tissue of mice in the DSS group was significantly increased (P < 0.0001), and compared with the DSS group, the IL-17 content in the JEC complex group was significantly decreased (P < 0.0001), which was 29.0067pg/mL and was close to the IL-17 content in the NC group (35.18 pg/mL). The specific cytokine IL-17 secreted by Th17 cells is involved in mediating tissue inflammation and inducing autoimmune diseases.
As can be seen from FIGS. 7 to 8, the JEC complex inhibited the polarization of colonic macrophages to M1 type, and promoted the polarization of colonic macrophages to M2 type. Co-localized mean optical density values of M1 macrophages represented by CD86 decreased from 659.281 (DSS group) to 421.199 (JEC complex group); co-localized mean optical density values of M2 macrophages represented by CD206 were upregulated from 350.794 (DSS group) to 648.394 (JEC complex group). Macrophages are important members of innate immunity, have strong plasticity as important immune cells of the body, play a significant role in maintaining the homeostasis of the body, and M1 macrophages have been shown to destroy the integrity of epithelial barriers. Taken together, JEC complexes can modulate the inflammatory response by modulating the subtype and distribution of colonic macrophages.
Example 2
The composition and the preparation method of this example are the same as example 1.
The lactobacillus paracasei JY062 composition obtained in the embodiment is applied to preparation of medicines, health-care products and functional foods for improving intestinal mucosa barrier damage.
The NF-kB signaling pathway regulated by the composition is a TLR4/MyD 88/NF-kB signaling pathway.
The related genes of the regulated signal channel are NF-kB p65, p-NF-kB p65, myD88, I kB, p-I kB and TLR4.
The function package for improving the intestinal mucosa barrier injury can up-regulate the expression quantity of IkB protein and mRNA, and down-regulate the expression quantities of NF-kB p65, p-NF-kB p65, myD88, p-IkB, TLR4 protein and NF-kB p65, myD88 and TLR4 mRNA.
The improvement of the barrier injury function of the intestinal mucosa comprises the improvement of the phenomena of epithelial cell shedding of the mucosal layer and intestinal permeability increase, the increase of the number of goblet cells, the improvement of histological injury score and the improvement of the injury of the colon mucosa tissue structure of the mouse.
Improving the barrier damage function of the intestinal mucosa comprises regulating the expression level and the average optical density value of Claudin-1, claudin-2, occludin, ZO-1 and mucin MUC2 mRNA.
Improving the barrier injury function of the intestinal mucosa comprises increasing the expression level and the average optical density value of Claudin-1, ocplus, ZO-1 and MUC2mRNA, and reducing the expression level and the average optical density value of Claudin-2 mRNA.
Application of lactobacillus paracasei and exopolysaccharide thereof in preparing medicines for improving intestinal mucosa barrier injury function.
Application of lactobacillus paracasei and exopolysaccharide thereof in preparing health care products for improving intestinal mucosa barrier injury function.
Application of lactobacillus paracasei and exopolysaccharides thereof in preparing functional food for improving intestinal mucosa barrier injury.
The dosage form of the medicine is any one of tablets, capsules, granules, powder and liquid preparations.
The health product is in the form of tablet, capsule, granule, powder or liquid.
The food can be made into tablet, capsule, granule, powder, or liquid.
The test animals are male C57BL/6J 8-week-old and 25-30g in weight, and purchased from Liaoning Biotechnology GmbH.
Animal grouping: the test animals were selected from 60 male animals C57BL/6J with age of 8 weeks and weight of 25-30g, and the acclimation after 1 week of basal feed acclimatization was randomly divided into 5 groups (n = 12), which were blank Control group (Control, NC), model group (3% DSS), and single fungus group (10% 9 CFU/mL，JY 062), monosaccharide group (600 mg/kg, EPS), saccharomycete complex group (10) 9 CFU/mL +600mg/kg, JEC), numbered with picric acid. Mice in the blank control group are fed with normal diet and free water in the whole experimental process (1-21 d), and mice in the intervention group (JY 062, EPS and JEC) are subjected to intragastric administration at regular time every day in the whole experimental period (8-21 d), and the intragastric administration dosage is 200 mu L. One week after gavage during modeling period (15-21 d), the remaining groups were induced by adding 3% DSS aqueous solution, except for blank control group.
1. Histopathological observation of the colon of mice:
taking out eyeballs, killing mice by a cervical-removing method, disinfecting the abdomen by 75% alcohol, opening the abdominal cavity in a sterile environment, finding out the tail end of the cecum, separating the tail end from the anus of the mice, taking out complete colon tissues, measuring pathological changes, taking the colon tissues of the mice fixed by 4% paraformaldehyde, washing, cutting, trimming, dehydrating by gradient ethanol, embedding by paraffin, slicing tissue slices (slices with the thickness of about 4 mu m), fixing glass slides, placing the slices in a 60 ℃ baking machine for 1h for preliminary dewaxing, HE dyeing (the specific operation is shown in the following table 1), observing morphological changes of the colon tissues under an optical microscope and taking pictures, and grading pathological damage conditions of various groups of colon tissues in the pictures mainly from four aspects: inflammatory cell infiltration, crypt morphology and lesion extent, the specific scoring criteria are shown in table 2:
TABLE 1HE staining procedure
TABLE 2 Colon histopathology scoring criteria
The final score is a superposition of the scores of the items.
2. Detecting the mRNA expression quantity of the tight junction protein and the TLR4/MyD 88/NF-kB signal channel by Real-time RT-PCR:
(1) Extraction of total RNA from mouse colon tissue:
100mg of colon tissue was removed from a-80 ℃ freezer, and pre-chilled sterile PBS was used as the homogenization medium, according to tissue weight: the volume of the homogenization medium was 1.
Taking the prepared mouse colon tissue homogenate, extracting the mouse colon tissue total RNA according to a method of a Simply P total RNA extraction reagent, collecting the RNA by using a 1.5mLRnase-free centrifuge tube after the extraction is finished, and performing subsequent experiments as soon as possible after the extraction because the RNA is easily interfered by factors such as the environment and the like, if the RNA cannot be used immediately, placing the RNA on an ice box, sealing the RNA by using a sealing film, labeling the RNA, placing the RNA in a refrigerator at the temperature of-80 ℃ for temporary storage after the time and the name are labeled; the experimental super clean bench is wiped and disinfected by chloroform in advance, the used instruments are treated by DEPC water, and the whole process is carried out on an ice box in a dark place during RNA extraction. The specific procedure was as above, using NanoDrop to determine OD 260 、OD 280 And OD 260 /OD 280 Value, purity and concentration of RNA determined.
(2) Reverse transcription cDNA Synthesis:
the total RNA with qualified extraction quality is reversely transcribed into cDNA by using a PrimeScriptTM RT Master Mix (Perfect Real Time) kit of TaKaRa company, a reverse transcription system is prepared according to the dosage specified by the kit in the kit, and the specific reaction system is shown in Table 3:
TABLE 3 reagent name and dosage table for kit
Reverse transcription was performed using a 7000PCR amplification apparatus using a pre-warmed machine, and the cDNA obtained by reverse transcription was stored at-20 ℃ for subsequent testing, with the specific reverse transcription reaction conditions shown in Table 4:
TABLE 4 reverse transcription reaction conditions
(3) RT-PCR reaction
Selecting a plurality of genes such as Claudin-1, occludin, ZO-1, MUC2, claudin-2, NF-kB p65, myD88, I kB, TLR4 and the like as target genes for RT-PCR research, and taking beta-actin as an internal reference gene; information of required genes is searched on NCBI, each gene specific Primer is designed by using Primer 5.0 software, PCR primers are synthesized by Shanghai Biotech limited company, and specific genes and Primer sequences are shown in Table 5.
TABLE 5 mouse primer information
Adjusting the concentration of the cDNA to a proper range, carrying out Real-time RT-PCR reaction on the cDNA obtained by reverse transcription by using a SYBR Premix Ex TaqTM II (Perfect Real-time) kit of TaKaRa company, and setting 3 parallel tests for each group, wherein the specific reaction system and the reaction conditions are shown in tables 6 and 7:
TABLE 6 Real-time RT-PCR reaction System (operating on ice)
TABLE 7 Real-time RT-PCR reaction conditions
Performing RT-PCR reaction by using an ABI QuantStudio 3 real-time fluorescent quantitative PCR instrument, performing Melding curve analysis on an amplification product of each gene, judging whether the PCR product is specifically amplified, and determining the specificity and the purity of the PCR product; analyzing the Ct value of each gene, calculating the delta Ct value and the delta Ct value of each gene, and evaluating the relative expression quantity of the target gene by adopting a 2-delta Ct relative quantification method.
Δ Ct = Ct sample-Ct internal reference
Δ Δ Ct = Δ Ct experimental group- Δ Ct control group.
3. Western Blotting detection of the expression level of key proteins of TLR4/MyD 88/NF-kB signaling pathway:
and analyzing signal channel key proteins in the colon tissues of the mice by using a Western blotting method. Extracting total protein in colon tissue, using BCA protein kit to quantitatively determine protein concentration, and performing protein immunoblotting operation after protein denaturation, wherein the specific steps are as follows. The optical density values of the target bands were analyzed using a GelDoc Go gel imaging system exposure development, IPWIN60 software processing system. By taking GAPDH as an internal reference, the expression changes of target proteins NF-kB p65, p-NF-kB p65, myD88, I kB, p-I kB and TLR4 are determined.
Target protein relative content = target band gray value/internal reference band gray value.
4. Immunohistochemistry method for detecting the expression of tight junction protein and mucin in colon tissue:
the colon tissue embedded and sliced by paraffin is incubated for 2 hours in an oven at 70 ℃, and then is subjected to xylene dewaxing, antigen retrieval, circle drawing on the periphery of the tissue by a histochemical pen, serum sealing, dropwise adding a primary antibody prepared according to a certain proportion and incubating overnight at 4 ℃, dropwise adding a secondary antibody of a corresponding species and incubating in a dark place for 50min, DAB color development by a color developing agent, hematoxylin counterstaining cell nucleus, 1% hydrochloric acid alcohol differentiation, ammonia water bluing, absolute ethyl alcohol dehydration and xylene transparent neutral gum sealing. The target proteins are zon-1, claudin-2, occludin and mucin MUC-2 in the colon, and are scored using Image J software.
5. Results and analysis
As can be seen from FIG. 9, the NC group mice had a substantially normal intestinal tissue structure, intact mucosal layer structure, regular arrangement, and no degeneration or shedding of epithelial cells; edema and inflammatory cell infiltration are not seen in the submucosa; goblet cell number did not decrease and black arrows indicate goblet cells. Histological lesions were scored lowest. The DSS group has serious abnormal intestinal tissue structure, partial crypt structure of a mucous layer disappears, and a large number of inflammatory cells and fibrous tissues proliferate as shown by yellow arrows; expansion of the remaining crypts, as indicated by the green arrows; erosion of mucosal epithelial cells sloughed off as indicated by red arrows; edema and inflammatory cell infiltration were seen in the submucosa as indicated by the blue arrows. The number of goblet cells is greatly reduced. Histological lesions scored highest with significant differences from both NC and JEC groups (p < 0.0001). JEC can reduce the exfoliation of epithelial cells on the mucosa layer and make the arrangement more compact; inflammatory cell infiltration is reduced; goblet cell numbers increased and histological lesion scores increased.
As can be seen from FIG. 10, compared with the NC group, the mRNA expression levels of NF- κ B p65, myD88 and TLR4 in colon tissues of mice are remarkably increased and the mRNA expression level of I κ B is remarkably reduced (p < 0.05) after DSS induction, which indicates that the transcription levels of TLR4, myD88 and NF- κ B p65 genes in the colon of the mice are increased and I κ B is opposite to the former. Compared with the DSS group, the mRNA expression levels of TLR4, myD88 and NF-kappa B p65 in the JEC group are obviously reduced, and the mRNA expression level of Ikappa B is obviously increased and is close to the level of mice in the NC group.
As can be seen from FIG. 11, compared with the NC group, the expression levels of NF- κ B p65, p-NF- κ B p65, myD88, p-I κ B and TLR4 proteins in colon tissues of mice after the DSS induction are significantly increased, and the expression level of I κ B proteins is significantly reduced. In contrast to the DSS group, the JEC group was inhibited in NF-. Kappa.B p65, p-NF-. Kappa.B p65, myD88, p-I.kappa.B, TLR4 protein expression, and I.kappa.B was in contrast. And the result is consistent with the result of RT-PCR, which shows that the JEC has the function of inhibiting a TLR4/MyD 88/NF-kB signal channel of a mouse.
As can be seen from FIG. 12, the expression level of Claudin-2 gene negatively correlated to the tight junction structure was significantly increased and ZO-1, claudin-1, occludin, MUC-2 were significantly decreased (p < 0.05) in the mice of the DSS group, as compared with the NC group. JEC can prevent the loss of TJ protein and mucin in intestinal tracts of DSS-induced colitis mice, protect the permeability of colon tissues of the mice, maintain the steady state of the intestinal tracts, and has more obvious protective effect on the TJ protein.
As can be seen from FIGS. 13 to 14, compared with the NC group, the average optical density of Claudin-2 negatively correlated to the tight junction structure in the mice of the DSS group is greatly increased, and ZO-1, claudin-1, occludin and MUC-2 are greatly reduced (p < 0.0001), which indicates that the intestinal mucosal barrier of the mice is seriously damaged; it is worth noting that the JEC group has the most obvious effect, and the barrier function of the intestinal mucosa can be further improved by adjusting the average optical density values of the tight connexins ZO-1, claudin-1, occludin and MUC-2 upwards and adjusting the average optical density value of Claudin-2 downwards.
The above description is only of the preferred embodiments of the present invention, and it should be noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the invention, and such modifications and adaptations are intended to be within the scope of the invention.
Claims (10)
1. The lactobacillus paracasei JY062 composition is characterized by comprising lactobacillus paracasei JY062 (B: (B) (B))Lactobacillus paracasei JY 062) and lactobacillus paracasei JY 062; the content of the lactobacillus paracasei JY062 is not less than 10 9 CFU/mL; the concentration of the exopolysaccharide is not lower than 30mg/mL.
2. A method of preparing a lactobacillus paracasei j062 composition according to claim 1, comprising the steps of:
step one, inoculating lactobacillus paracasei JY062 into a sterilized MRS liquid culture medium according to the inoculation amount of 5 percent, wherein the initial concentration is 1.5 multiplied by 10 9 CFU/mL；
Step two, adding the compound carbon source in an equal amount by using the optimized compound carbon source MRS liquid culture medium; culturing at 34 deg.C in a fermenter at 100rpm/min for 25h, and supplementing 20% w/v ammonia water during fermentation; after fermenting for 12 hours, starting to supplement 100mL/30min of MRS liquid culture medium until the end, and collecting bacterial liquid;
centrifuging the bacterial liquid, taking the supernatant I, and repeating the step twice;
step four, taking the supernatant I, and concentrating the volume to 1/3 of the original volume to obtain a culture medium;
step five, inactivating enzyme of the culture medium, cooling to room temperature, and collecting supernatant liquid II;
removing protein from the supernatant II, and centrifuging to obtain a supernatant III;
precipitating the supernatant III with ethanol, centrifuging and taking the precipitate;
step eight, resuspending the pellet in deionized water to obtain polysaccharide solution, placing the polysaccharide solution in an MD34 dialysis bag, wherein the molecular weight cut-off is as follows: 8KD-14KD, dialyzing in deionized water at 4 deg.C for 48h, and replacing deionized water every 8 h;
and step nine, pouring the dialyzed polysaccharide supernatant into a flat plate, placing the flat plate in a refrigerator at the temperature of minus 80 ℃ for pre-freezing overnight, then carrying out freeze drying for 24 hours, and carrying out freeze drying to obtain the exopolysaccharide.
3. The method according to claim 2, wherein in the first step, the MRS liquid medium comprises the following components: 10g/L peptone, 8g/L beef powder, 4g/L yeast powder, 20g/L glucose, 2g/L diammonium hydrogen citrate, 2g/L dipotassium hydrogen phosphate, 5g/L sodium acetate, 0.2g/L magnesium sulfate, 0.04g/L manganese sulfate and 1g/L Tween-80; dissolving 52.24g of the components in 1000mL of distilled water, stirring by a glass rod, carrying out autoclaving at 121 ℃ for 15min, and obtaining the MRS liquid culture medium.
4. The preparation method according to claim 2, wherein in the second step, the optimized composite carbon source MRS liquid medium comprises the following components: 10g/L peptone, 8g/L beef powder, 4g/L yeast powder, 2g/L diammonium hydrogen citrate, 2g/L dipotassium hydrogen phosphate, 5g/L sodium acetate, 0.2g/L magnesium sulfate, 0.04g/L manganese sulfate, 1g/L Tween-80, 3.33g/L fructose, 3.33g/L mannose, 3.33g/L trehalose, 3.33g/L glucose, 3.33g/L galactose and 3.33g/L lactose; dissolving 52.24g of the components in 1000mL of distilled water, stirring with a glass rod, carrying out high-pressure sterilization at 121 ℃ for 15min, and obtaining the optimized composite carbon source MRS liquid culture medium.
5. The method according to claim 2, wherein the centrifugation process comprises: centrifuging at 10000r/min and 4 deg.C for 15min.
6. The preparation method according to claim 2, wherein in the fifth step, the enzyme deactivation process is: heating in boiling water for 10min.
7. The preparation method according to claim 2, wherein in the sixth step, the protein removal process comprises: 80% w/v of trichloroacetic acid was added to the supernatant II to a final concentration of 10% w/v, followed by stirring for 5min and standing at 4 ℃ for 10h,10000r/min, and centrifuging at 4 ℃ for 15min to remove proteins.
8. The preparation method according to claim 2, wherein in the seventh step, the alcohol precipitation process is as follows: adding 2-3 times volume of anhydrous ethanol into the supernatant III to make the final concentration 70%, standing overnight at 4 deg.C, centrifuging at 10000r/min at 4 deg.C for 15min.
9. Use of a lactobacillus paracasei JY062 composition according to claim 1 for the preparation of health products and functional foods for enhancing intestinal immunocompetence.
10. The application of the lactobacillus paracasei JY062 composition according to claim 1 in preparing medicines, health-care products and functional foods for improving intestinal mucosal barrier injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211072208.5A CN115300531B (en) | 2022-09-02 | 2022-09-02 | Lactobacillus paracasei JY062 composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211072208.5A CN115300531B (en) | 2022-09-02 | 2022-09-02 | Lactobacillus paracasei JY062 composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115300531A true CN115300531A (en) | 2022-11-08 |
| CN115300531B CN115300531B (en) | 2023-03-24 |
Family
ID=83865917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211072208.5A Active CN115300531B (en) | 2022-09-02 | 2022-09-02 | Lactobacillus paracasei JY062 composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115300531B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116042477A (en) * | 2023-01-05 | 2023-05-02 | 东北农业大学 | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products |
| CN116162570A (en) * | 2023-01-31 | 2023-05-26 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN117586926A (en) * | 2024-01-18 | 2024-02-23 | 东北农业大学 | Lactobacillus paracasei LP-116, LP-116 metagen composition, and preparation method and application thereof |
| CN117603885A (en) * | 2024-01-18 | 2024-02-27 | 东北农业大学 | Lactobacillus paracasei LP-116 and application thereof in preparation of products for regulating intestinal barrier damage |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109679355A (en) * | 2018-12-14 | 2019-04-26 | 华南农业大学 | A kind of antibacterial film and its application |
| CN110893195A (en) * | 2019-09-30 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus paracasei ET-22 with function of relieving intestinal inflammation |
| WO2021098764A1 (en) * | 2019-11-20 | 2021-05-27 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei k56 in relieving intestinal inflammation |
| CN112869167A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Application of lactobacillus paracasei K56 in improving intestinal bacterial infection resistance and intestinal immunity |
| CN114344344A (en) * | 2022-01-05 | 2022-04-15 | 东北农业大学 | Application of lactobacillus reuteri in relieving high-fat diet induced obesity of mice and compound containing lactobacillus reuteri |
| CN114377037A (en) * | 2022-02-22 | 2022-04-22 | 内蒙古蒙牛乳业（集团）股份有限公司 | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar |
-
2022
- 2022-09-02 CN CN202211072208.5A patent/CN115300531B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109679355A (en) * | 2018-12-14 | 2019-04-26 | 华南农业大学 | A kind of antibacterial film and its application |
| CN110893195A (en) * | 2019-09-30 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus paracasei ET-22 with function of relieving intestinal inflammation |
| WO2021098764A1 (en) * | 2019-11-20 | 2021-05-27 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei k56 in relieving intestinal inflammation |
| CN112869167A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Application of lactobacillus paracasei K56 in improving intestinal bacterial infection resistance and intestinal immunity |
| CN114344344A (en) * | 2022-01-05 | 2022-04-15 | 东北农业大学 | Application of lactobacillus reuteri in relieving high-fat diet induced obesity of mice and compound containing lactobacillus reuteri |
| CN114377037A (en) * | 2022-02-22 | 2022-04-22 | 内蒙古蒙牛乳业（集团）股份有限公司 | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar |
Non-Patent Citations (2)
| Title |
|---|
| JIAYUAN ZHAO等: "A Potential Synbiotic Strategy for the Prevention of Type 2 Diabetes: Lactobacillus paracasei JY062 and Exopolysaccharide Isolated from Lactobacillus plantarum JY039", 《NUTRIENTS》 * |
| 张宇等: "一株高产胞外多糖降血糖副干酪乳杆菌JY062（TD062）的黏附性与耐受性评价", 《中国乳品工业》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116042477A (en) * | 2023-01-05 | 2023-05-02 | 东北农业大学 | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products |
| CN116042477B (en) * | 2023-01-05 | 2024-01-30 | 东北农业大学 | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products |
| CN116162570A (en) * | 2023-01-31 | 2023-05-26 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN116162570B (en) * | 2023-01-31 | 2023-10-17 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN117586926A (en) * | 2024-01-18 | 2024-02-23 | 东北农业大学 | Lactobacillus paracasei LP-116, LP-116 metagen composition, and preparation method and application thereof |
| CN117603885A (en) * | 2024-01-18 | 2024-02-27 | 东北农业大学 | Lactobacillus paracasei LP-116 and application thereof in preparation of products for regulating intestinal barrier damage |
| CN117603885B (en) * | 2024-01-18 | 2024-04-05 | 东北农业大学 | Lactobacillus paracasei LP-116 and application thereof in preparation of products for regulating intestinal barrier damage |
| CN117586926B (en) * | 2024-01-18 | 2024-04-16 | 东北农业大学 | Lactobacillus paracasei LP-116, LP-116 metagen composition, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115300531B (en) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115300531B (en) | Lactobacillus paracasei JY062 composition and preparation method and application thereof | |
| US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
| CN112646744B (en) | Application of lactobacillus reuteri in preventing and relieving ulcerative colitis | |
| CN113604384B (en) | Lactobacillus rhamnosus and application thereof | |
| Raheja et al. | Lactobacillus acidophilus stimulates the expression of SLC26A3 via a transcriptional mechanism | |
| CN112481175B (en) | Lactobacillus rhamnosus capable of preventing and relieving ulcerative colitis and application thereof | |
| CN112625964A (en) | Application of lactobacillus rhamnosus in prevention and alleviation of ulcerative colitis | |
| CN115216422B (en) | Lactobacillus rhamnosus and application thereof | |
| CN113151039A (en) | Lactobacillus plantarum for relieving ulcerative colitis and application thereof | |
| CN114854638B (en) | Lactobacillus paracasei capable of efficiently expressing adenosine deaminase mRNA to relieve colonitis | |
| CN112760250B (en) | Rumen lactobacillus for relieving colitis and application thereof | |
| WO2021143621A1 (en) | Anaerostipes sp b2131 strain and use thereof in inflammatory bowel diseases | |
| CN116731929A (en) | Lactobacillus mucilaginosus ZS40 and application thereof | |
| CN115992059B (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis | |
| WO2018112740A1 (en) | Lactobacillus gasseri, culture method therefor and application thereof | |
| CN111560325B (en) | Lactobacillus fermentum capable of regulating intestinal tight junction protein and application thereof | |
| CN115996736A (en) | Novel lactobacillus reuteri strain and use thereof | |
| CN110331118B (en) | Bifidobacterium adolescentis CCFM1061, fermented food thereof and preparation method of microbial inoculum | |
| CN117821313A (en) | Lactobacillus rhamnosus capable of remarkably improving numbers of enteric neurons and glial cells and application thereof | |
| CN115612652B (en) | Lactobacillus plantarum AS21 and application thereof in preventing ulcerative colitis | |
| CN111714524A (en) | Application of lactobacillus murinus in preparation of composition for preventing and treating intestinal ischemia reperfusion injury | |
| CN114410531B (en) | Bifidobacterium longum CCFM1216 for reducing blood plasma TMAO and relieving and preventing atherosclerosis and application thereof | |
| CN112646743B (en) | Lactobacillus reuteri CCFM1134 for preventing and relieving ulcerative colitis and application thereof | |
| CN113913330B (en) | Lactobacillus plantarum for regulating OVA-specific IgE and application thereof | |
| CN114410532B (en) | Bifidobacterium longum capable of reducing plasma trimethylamine oxide and cecum trimethylamine levels and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |